Drug Profile
VT 111
Alternative Names: Serine protease inhibitor-1; SERP-1; VT-111; VT-111a; VT-111bLatest Information Update: 16 Jan 2017
Price :
$50
*
At a glance
- Originator Viron Therapeutics
- Class Anti-inflammatories; Antirheumatics; Serpins
- Mechanism of Action Immunosuppressants; Peptide hydrolase inhibitors; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Acute coronary syndromes
Highest Development Phases
- No development reported Acute coronary syndromes; Transplant rejection
- Discontinued Atherosclerosis; Coronary artery restenosis; Reperfusion injury; Rheumatoid arthritis
Most Recent Events
- 07 Sep 2015 No recent reports on development identified - Phase-II for Acute coronary syndromes in USA and Canada (IV)
- 07 Sep 2015 No recent reports on development identified - Preclinical for Transplant rejection (Prevention) in Canada (IV)
- 20 Dec 2010 VT 111 is available for licensing for cardiac stenting (\www.vironinv.com\)